Gestational diabetes mellitus: a (nearly) perfect mouse model

Abstract

Diabetes mellitus (DM) is a massive global problem with projected global economic impact, including direct and indirect productivity costs, increasing from $1.3 trillion USD to approximately $2.2 trillion USD by 2030 despite international interventions (Bommer et al. 2018). In addition, a massive increase in prevalence was predicted across most age groups, from 8.8% to 10% in the baseline scenario. Included in these values is a subtype of DM, gestational diabetes mellitus (GDM), characterized by onset of hyperglycaemia only in the gestational period. According to the WHO in 2013, the global prevalence of GDM is nearly 17% in pregnant female cohorts when diagnostic thresholds set by the International Association of the Diabetes and Pregnancy Study Groups are applied (Feig et al. 2018) and increasing due to a variety of reasons, including the increasing incidence of often comorbid obesity. As pregnancy progresses, the surge of pregnancy hormones including prolactin, progesterone and placental lactogen promote a temporary state of mild insulin resistance, allowing blood glucose to remain high and supply the fetus via the placenta (Plows et al. 2018). Maternal placental hormones then trigger a response in pancreatic β-cells to attempt to restore euglycaemia – β-cells and often α-cells of the pancreas undergo hypertrophy and hyperplasia. In a recent issue of The Journal of Physiology, Szlapinski and colleagues demonstrated that pregnant mice classified as having GDM displayed pancreata with significantly decreased αand β-cell mass, corresponding to an overall decrease in insulin production and secretion, and therefore a globally reduced glucose sensitivity (Szlapinski et al. 2019). This pathology represents approximately 80% of GDM cases, which are classified based on β-cell dysfunction with previous history or worsening peripheral insulin resistance (Plows et al. 2018), indicating a diabetic disorder that includes aspects of all three major categories of the disease (Type I, Type II and other). Since early treatment of GDM can reduce the incidence of pre-eclampsia, fetal overgrowth and more in the fetus (Feig et al. 2018), accurate diagnosis and adequate treatment is paramount to the health of the child. Though the pathophysiology of GDM is relatively well understood, few effective preventative treatments and measures work. Live human models of GDM, though, can be difficult to study, with both physical and ethical barriers that come with placental sampling. Previous models in rodents have induced GDM with low doses of streptozotocin (STZ) in combination with high sucrose and fat diets among other factors (Aziz et al. 2016). While these models achieved a snapshot of GDM, they did not demonstrate the progressive glucose intolerance typical of GDM. Szlapinski and colleagues targeted this issue in their study. They aimed to develop a diet-induced progressive mouse model of gestational glucose intolerance, whereby the intolerance mirrored human gestational diabetes. This generational model was successfully accomplished through timed pregnancies by mating male and female mice, alongside the establishment of mouse oestrous cycling. After female pregnant mice were housed separately, Szlapinski and colleagues randomly divided this group (F0) into two isocaloric diet groups: a control (C) group, which consisted of 24 dams that were fed a 20% protein diet, and a group of 21 dams that were fed a low protein (LP) diet, which consisted of 8% protein. Female offspring (F1) were then separated into pregnant and non-pregnant groups. In order to create an animal model of GDM, at maturity, F1 females were mated with males on a control diet. In order to test glucose tolerance, F0 and F1 generation mice underwent an intraperitoneal glucose tolerance test at separate times, according to the previously described techniques. To localize and quantify insulin for immunohistochemistry, insulin-expressing cells were colocalized with the proliferative marker Ki-67, allowing accurate identification of β-cells and their proliferative rate. The quantification of β-cells thus allowed the definition and quantification of pancreatic islets, which served as a basis for comparing β-cell growth and apoptosis. In the F0 mice, Szlapinski and colleagues showed that there were no noticeable differences between the C and the LP diet treatment groups. Maternal weight gain and litter size was consistent and an intraperitoneal glucose tolerance test (IPGTT) was performed at 1 month postpartum which indicated that there was no difference in glucose tolerance across the two groups. However, in the F1 generation, the offspring born to LP diet dams weighed less at birth compared to the C diet offspring (1.25 ± 0.02 g vs. 1.34 ± 0.03 g, P < 0.05). The offspring of LP diet mice continued to weigh less throughout life. The weight difference was particularly apparent during late gestation where low protein pregnant (LPP) females weighed significantly less than the control pregnant (CP) females ((12.78 ± 1.22 g vs. 15.24 ± 1.44 g, P < 0.001). During pregnancy the LPP and the CP groups showed no differences in fetal resorption. Fasting blood glucose levels in LPP and CP females demonstrated no significant differences but by gestational day (GD) 18, the LPP females had significantly higher non-fasting blood glucose compared to CP mice. The β-cell mass (BCM) in LPP females was also drastically lower than the expansion of BCM in CP females, indicating that changes in the pancreas contribute to glucose intolerance. Szlapinski and colleagues were able to determine that the reduced BCM was caused by reduced proliferation of β-cells in LPP females. The mean islet size was reduced in the LPP females at GD18 even though there was no difference in β-cell size. However, the number of small islets in LPP compared to CP females was reduced. In the presence of low glucose (2.8 mmol/L), both the LPP and the CP islets at GD18 showed similar insulin secretion. However, when subjected to high glucose (16.7 mmol/L), the LPP islets had much lower insulin secretion.